Urgent call for increased measles vaccination in the EU/EEA

NewsGuard 100/100 Score

Measles cases are expected to continue increasing in the European Union and European Economic Area (EU/EEA) in the coming months due to sub-optimal vaccination coverage for measles-containing vaccines (MCV) in a number of EU/EEA countries, the high probability of importation from areas experiencing high circulation and the fact that the coming months represent the seasonal peak of the virus.

The evaluation is included in a recent ECDC assessment Measles on the rise in the EU/EEA: Considerations for public health response. ECDC data show that in January and early February 2024, the number of EU/EEA countries reporting measles cases has increased. At least seven deaths have been reported from two countries.

Nobody should die from measles. The increase in cases of measles, a highly contagious, but vaccine-preventable disease, is a stark reminder that all Member States should maximize efforts to achieve and maintain high vaccination coverage for all vaccine-preventable diseases. Vaccines are a safe and effective way to reduce the health burden of infectious diseases and avoid unnecessary loss of life." 

Andrea Ammon, ECDC Director

Measles poses a threat to individuals of all age groups, which highlights the importance of maintaining high vaccination coverage across the entire population. The highest potential impact of measles, due to the high morbidity following infection, is for infants too young to be immunized (usually those under the age of 12 months, depending on national schedules). Unvaccinated children under five years old are also at increased risk, as measles can have several complications in this age group. Additionally, other groups such as the immunocompromised are at risk of severe outcomes from measles. 

Stella Kyriakides, the European Union Commisioner for Health and Food Safety, added: "The rising trend in measles cases across Europe is worrying. This is an extremely contagious disease which can cause serious complications, particularly for children and vulnerable persons. The good news is that it is a disease which is preventable through vaccination and that there are plenty of safe and effective vaccines available in the EU. When we see measles outbreaks, we know there is a gap in vaccinations. I urge everyone to check their vaccination status and parents to make sure their children and young person's vaccines are up to date. Vaccination protects and saves lives, it is one of our strongest tools against measles and many other infectious diseases."

Measles spreads very easily, therefore, high vaccination coverage of 95% or higher of the population vaccinated with two doses of the vaccine, is essential to interrupt transmission in a country or community. 

Efforts should therefore be intensified to identify and reach unvaccinated or partially vaccinated populations. Equity in access to immunization should be ensured especially for vulnerable populations like migrants, ethnic minorities, and those who live in crowded settings e.g. refugee camps.

High-quality surveillance systems are essential for early detection, response, and control of local measles outbreaks. In addition, enhanced laboratory diagnostic capacity facilitates to track virus genotypes and identify transmission chains.

Raising awareness on the measles situation among health professionals across various specialties is important to ensure timely diagnosis, especially in older children and adults.

Efforts should be also made to identify the reasons for low vaccine uptake in communities and implement tailored interventions. These include risk communication and community-based initiatives, including towards underserved population groups.

ECDC remains committed to collaborate with EU/EEA countries and international partners to assist countries in increasing vaccination coverage and protect public health.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lurie Children's Hospital administers first gene therapy for Duchenne muscular dystrophy in Illinois